Zogenix cuts 55 jobs, awaits FDA Zohydro decision
This article was originally published in Scrip
Zogenix will reduce its 148-employee work force by 37%, cutting 55 jobs as the San Diego-based company awaits a US FDA decision on approval for the chronic pain drug Zohydro ER.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.